The monoclonal antibodies (mAb) constitute a new therapeutic tool in cardiovascular medicine, based in the development of the molecular biology in this area.The understanding of therapeutic principles, types and mechanism of action of these drugs is essential for proper use and management of adverse reactions.We discuss the profile of the PCSK-9 inhibitors, the
